Investors
Financials
Financial Calendar
Jan 25, 2024 – Trading update Q4 2023
Apr 25, 2024 – Financial Results FY 2023 & Trading Update Q1 2024
Jun 6, 2024 – Annual General Meeting
Jul 25, 2024 – Trading Update Q2 2024
Oct 30, 2024 – Financial Results H1 2024 and Trading Update Q3 2024
Financial Calendar
Jan 25, 2024 – Trading update Q4 2023
Apr 25, 2024 – Financial Results FY 2023 & Trading Update Q1 2024
Jun 6, 2024 – Annual General Meeting
Jul 25, 2024 – Trading Update Q2 2024
Oct 30, 2024 – Financial Results H1 2024 and Trading Update Q3 2024
Mauna Kea Technologies Announces its Sales and Achievements For the Second Quarter 2024
2023 Annual Financial Report
Mauna Kea Technologies Reports Full Year 2023 Results and Q1 2024 Sales
Mauna Kea Technologies Executes Agreement to Restructure its Existing Loan Agreement with the European Investment Bank
Mauna Kea Technologies Announces Initiation of Coverage by EuroLand Corporate
Mauna Kea Technologies Reports Full Year 2023 Sales of €10.5m, Up +42% vs 2022
Mauna Kea Technologies Reports 74% Increase in 9-Month 2023 Sales
Mauna Kea Technologies Reports H1 2023 Financial Results
Mauna Kea Technologies Reports Second Quarter and First Half 2023 Revenue
2022 Universal Registration Document
Mauna Kea Technologies Reports 2022 Annual Results
Mauna Kea Technologies announces the coverage of its stock by Portzamparc – Groupe BNP Paribas
News
Mauna Kea Technologies Announces its Sales and Achievements For the Second Quarter 2024
Mauna Kea Technologies Unveils CellTolerance, a Subsidiary Dedicated to its Unique Program for the Detection and Treatment of Food Intolerances
